Search results
Results from the WOW.Com Content Network
In ovarian hyperstimulation combined with IUI, women aged 38–39 years appear to have reasonable success during the first two cycles, with an overall live birth rate of 6.1% per cycle. [12] However, for women aged ≥40 years, the overall live birth rate is 2.0% per cycle, and there appears to be no benefit after a single cycle of COH/IUI. [ 12 ]
Ovarian hyperstimulation syndrome (OHSS) is a medical condition that can occur in some women who take fertility medication to stimulate egg growth, and in other women in sporadic cases. Most cases are mild, but rarely the condition is severe and can lead to serious illness or even death.
Controlled ovarian hyperstimulation is generally part of in vitro fertilization, and the aim is generally to develop multiple follicles (optimally between 11 and 14 antral follicles measuring 2–8 mm in diameter), [5] followed by transvaginal oocyte retrieval, co-incubation, followed by embryo transfer of a maximum of two embryos at a time. [6]
Why does ovarian hyperstimulation syndrome occur? OHSS is a potential side effect of stimulating the ovaries to produce multiple eggs at the same time either during the first part of an IVF cycle ...
Clomid if often used in the case of an intrauterine insemination (IUI). Donor egg. ... Ovarian reserve. Women are born with a certain number of eggs, and ovarian reserve is a term used to describe ...
Final maturation induction using a GnRH agonist is recommended in women with cancer undergoing fertility preservation, because ovarian hyperstimulation syndrome is associated with an increased risk of arterial thrombotic events such as stroke, myocardial infarction and peripheral arterial embolism, and this risk can add to an already increased ...
Then she’ll discuss the possibility of conducting an ovarian reserve test to determine how many eggs the patient has left. This can be done with either a blood test or another ultrasound exam to ...
Common side effects include ovarian enlargement, hot flash, abdominal distention, breast discomfort, and hyperlipidemia. Rare adverse effects are ovarian hyperstimulation syndrome and visual abnormalities. [13] Long-term use may raise risk of ovarian cancer, such that long-term therapy (more than 6 cycles) is not recommended. [13] [14]